Syros stock craters after lead cancer therapy flops in Phase III trial

Syros Pharmaceuticals faced a significant stock decline due to the failure of its lead cancer therapy, tamibarotene, in a Phase III trial for higher-risk myelodysplastic syndrome patients. The company plans to discontinue the study, review results, and evaluate next steps.